Pharma Stock engaged in offering a wide range of herbal remedies, health care, and veterinary health care products jumped upto 5 percent in the day’s trade upon receiving a new work order worth ~Rs. 20 Lakhs.
Price Action
With a market capitalization of Rs. 67 Crores, the shares of Shelter Pharma Limited were trading at Rs. 57.60 per equity share, up 4.73 percent from its previous day’s close price of Rs. 55.
What Happened
Shelter Pharma Limited engaged in manufacturing and supplying pharmaceuticals has secured a new work order from Firstvet Veterinary Medicines Trading LLC for the supply of Lactic Acid Buffer Bottles for a consideration of $23,000 or Rs. 19.55 Lakhs.
About the Company
Shelter Pharma Limited is an India-based pharmaceutical manufacturing company, engaged in offering a wide range of herbal remedies to millions around the world. It provides human health care and veterinary health care products.
Its human health care products include Adalpin-Sp-Tablet, Alkaliser syrup, B-Kleen Liquid, Baldeepak, Banatone-Syrup, Beta Gulcan, Bipinyl, Chymocure, Cocoment Ointment, Cough Nal and Dia Dys Tablet.
Its veterinary health care products include Agrical Powder, Amino vit WSP Powder, Anical Oral, Bijrol Liquid, Calciphos Bolus, D Cal-P, Diavet Powder / Bolus, Digesta Powder, Ekkol Liquid, and many others.
Financials and Ratios
Its revenue from operations grew by 25 percent from Rs. 19.31 Crores in H1FY24 to Rs. 24.06 Crores in H1FY25, accompanied by profits of Rs. 3.10 Crores to Rs. 3.54 Crores.
In terms of Return ratios, it has reported a return on equity (ROE) of 16.92 percent, and a Return on capital employed (ROCE) of 22.17 percent. It has reported a debt-to-equity ratio of 0.03.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
